Shanghai RAAS Blood Products Co Ltd Class A (002252) — Cash Flow-to-Debt Ratio
Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Cash Flow-to-Debt Ratio of -0.16x as of December 2025, meaning its operating cash flow of CN¥-843.75 Million could theoretically repay 0% of its total liabilities (CN¥5.33 Billion) in one year. See 002252 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Shanghai RAAS Blood Products Co Ltd Class A Cash Flow-to-Debt Ratio (2005–2025)
Historical debt coverage capacity for Shanghai RAAS Blood Products Co Ltd Class A across 21 annual periods. Also explore 002252 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
Year-by-year debt coverage analysis for Shanghai RAAS Blood Products Co Ltd Class A. For market capitalisation and broader financial context, see 002252 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | CN¥-104.89 Million | CN¥5.34 Billion | ▲ +93.1% |
| 2024 | -0.29x | CN¥-482.06 Million | CN¥1.69 Billion | ▼ -128.5% |
| 2023 | 1.00x | CN¥2.28 Billion | CN¥2.28 Billion | ▼ -4.7% |
| 2022 | 1.05x | CN¥1.73 Billion | CN¥1.64 Billion | ▲ +8.0% |
| 2021 | 0.97x | CN¥1.29 Billion | CN¥1.33 Billion | ▼ -69.8% |
| 2020 | 3.21x | CN¥1.17 Billion | CN¥363.74 Million | ▲ +33.3% |
| 2019 | 2.41x | CN¥872.69 Million | CN¥361.95 Million | ▲ +356.1% |
| 2018 | 0.53x | CN¥262.50 Million | CN¥496.56 Million | ▲ +288.5% |
| 2017 | 0.14x | CN¥268.76 Million | CN¥1.98 Billion | ▼ -68.1% |
| 2016 | 0.43x | CN¥638.22 Million | CN¥1.50 Billion | ▼ -52.8% |
| 2015 | 0.90x | CN¥762.42 Million | CN¥843.64 Million | ▲ +46.5% |
| 2014 | 0.62x | CN¥465.96 Million | CN¥755.16 Million | ▲ +424.2% |
| 2013 | -0.19x | CN¥-90.11 Million | CN¥473.37 Million | ▼ -113.6% |
| 2012 | 1.40x | CN¥263.46 Million | CN¥188.79 Million | ▼ -35.5% |
| 2011 | 2.16x | CN¥178.03 Million | CN¥82.26 Million | ▲ +7.1% |
| 2010 | 2.02x | CN¥200.21 Million | CN¥99.12 Million | ▲ +7.8% |
| 2009 | 1.87x | CN¥116.01 Million | CN¥61.88 Million | ▲ +33.1% |
| 2008 | 1.41x | CN¥107.64 Million | CN¥76.42 Million | ▲ +9.4% |
| 2007 | 1.29x | CN¥175.71 Million | CN¥136.53 Million | ▲ +304.4% |
| 2006 | 0.32x | CN¥53.58 Million | CN¥168.39 Million | ▼ -39.9% |
| 2005 | 0.53x | CN¥54.02 Million | CN¥101.93 Million | — |